ANI Pharma (ANIP) Tops Q1 EPS by 86c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.17, $0.86 better than the analyst estimate of $0.31. Revenue for the quarter came in at $106.8 million versus the consensus estimate of $83.42 million.

GUIDANCE:

ANI Pharma sees Q2 2023 EPS of $2.99-$3.45, versus the consensus of $2.43. ANI Pharma sees Q2 2023 revenue of $385-410 million, versus the consensus of $371.3 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• KeyBanc Upgrades Nucor (NUE) to Overweight